Fusion Antibodies is a high-risk AIM micro-cap turnaround where OptiMAL® licensing could unlock asymmetric upside, but weak cash flow, dilution risk, and uncertain commercial adoption remain decisive hurdles.
Overview
Fusion Antibodies is a Belfast-based AIM-listed pre-clinical antibody CRO serving biotech, pharma, diagnostics, and veterinary customers. It provides antibody discovery, humanisation, sequencing, production, purification, and cell line development through proprietary platforms including CDRx™ and OptiMAL®. The company’s appeal lies in deep scientific specialization, flexibility, and validated technology rather than scale. Its future depends on converting OptiMAL® from a lab-based service into a licensing platform capable of generating high-margin upfront fees, milestones, and royalties.